尼妥珠单抗治疗晚期肺鳞癌的临床观察

目的：观察尼妥珠单抗治疗晚期肺鳞癌的临床疗效和安全性。方法回顾性分析12例使用尼妥珠单抗治疗肺鳞癌患者的临床资料，并进行疗效和安全性评估。结果3例ⅢB期患者中，2例一线使用尼妥珠单抗联合同步放化疗治疗，病情进展（PD）；1例二线使用尼妥珠单抗联合化疗，病情稳定（SD），无进展生存时间为12.0个月。9例Ⅳ期患者中，7例一线使用尼妥珠单抗联合化疗，部分缓解（PR）患者4例，SD患者3例，客观有效率（ORR）57.1%，疾病控制率（DCR）100%；2例二线使用尼妥珠单抗联合化疗，均为SD。治疗期间出现的不良反应包括：中性粒细胞减少7例（58.3%），血小板减少3例（25.0%），呕吐1例（8.3%），乏力3例（25.0%），神经毒性5例（41.7%），脱发10例（83.3%）。这些不良反应多与联合使用的化疗药物相关。结论尼妥珠单抗联合化疗治疗晚期肺鳞癌的客观有效率、疾病控制率高，且不良反应可控，值得临床推广。

Clinical observation of nimotuzumab in advanced lung squamous cell carcinoma

Objective To evaluate the efficacy and safety of nimotuzumab in the treatment of advanced lung squa-mous cell carcinoma. Method A retrospective analysis of clinical data was conducted in 12 patients with advanced lung squamous cell carcinoma, who were administered with nimotuzumab, and the efficacy and safety were evaluated accord-ingly. Result Among three patients of stageⅢB lung cancer, 2 patients were treated by nimotuzumab combined with concurrent chemoradiation as first line treatment, but diseases progressed (PD) in both patients;one patient treated by ni-motuzumab with chemotherapy as second line treatment had stable disease (SD) and 12 months of progression-free sur-vival (PFS). Among 9 patients with stageⅣlung cancer, 7 cases were treated by nimotuzumab and chemotherapy as first line treatment, with 4 cases of partial remission (PR) and 3 cases of SD. Objective response rate (ORR) of these seven pa-tients was 57.1%, and disease control rate (DCR) was 100%;two patients treated by nimotuzumab with chemotherapy as second line treatment had SD. All the adverse effects were manageable, including 7 cases (58.3%) of neutropenia, 3 cases (25.0%) of thrombocytopenia, 1 case (8.3%) of vomiting, 3 cases (25.0%) of fatigue, 5 cases (41.7%) of peripheral senso-ry neuropathy, and 10 cases (83.3%) of alopecia. All were chemotherapy-related effects. Conclusion The objective re-sponse rate and disease control rate of nimotuzumab combined with chemotherapy are high in patients with advanced lung squamous carcinoma, and adverse effects are manageable, making it a clinically practicable therapy.